Nabla Bio

We use AI to design antibodies for intractable diseases

Y CombinatorSummer 2020ActiveHealthcareDrug Discovery and DeliveryAI-powered Drug Discovery

What they do

Problem

Drug developers struggle to discover and optimize antibodies for difficult disease targets while avoiding manufacturability and toxicity issues.

Solution

An AI- and high-throughput experimentation platform that designs antibodies to bind specific targets at the right epitope with reduced development risks.

Who it's for

Pharmaceutical and biotechnology companies developing antibody therapeutics.

Founders

Surge Biswas

Founder

Currently building Nabla Bio. I'm a scientist with 10+ years of experience with using synthetic biology and machine learning to engineer everything from the microbiome to proteins. I recently completed my PhD from George Church's lab at Harvard.

LinkedIn · X

Frances Anastassacos

Founder

Currently building Nabla Bio! I've spent the last 8 years applying my chemistry training to problems in biology and specifically synthetic biology. I did my PhD at Harvard (Class 2019, BBS) and spent some time in biotech VC.